Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

(Reuters) - Merck& Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.

Source: Reuters: Health - April 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news